Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAMPath and BELimumab for the Induction of Donor Specific Humoral Transplant Tolerance in Sensitized Kidney Transplant Recipients To Improve Long-Term Allograft Survival

NCT03591380 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT03591380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03591380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAMPath and BELimumab for the Induction of Donor Specific Humoral Transplant Tolerance in Sensitized Kidney Transplant Recipients To Improve Long-Term Allograft Survival
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Terminated
Start date
May 14, 2019
Completion date
December 3, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation